Thousands could benefit from first immunotherapy for severe birch tree pollen allergy We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

This guidance has been updated and replaced by osteoarthritis in over 16s: diagnosis and management ...

This guideline has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) [NG245] ...

COVID-19 All NICE products on COVID-19. Includes any guidance and advice. Published products on this topic (13) ...

This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and ...

COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community NICE guideline NG163 Published: 03 April 2020 Last updated: 13 October 2020 ...

Questions to ask about mental health problems in pregnancy and the year after birth These questions may help you discuss your condition or the treatments you have been offered with healthcare ...

Suggested remit: To appraise the clinical and cost effectiveness of nusinersen and risdiplam within their marketing authorisations for treating spinal muscular atrophy ...

Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane ...